AVIR · Atea Pharmaceuticals, Inc.
$4.81
-0.06 (-1.23%)
At close · Jul 22
Market Cap
$384.93M
Shares
80.03M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$351.37M
+622.5%
FY2021
Net Income
-$158.35M
+6%
FY2025
Operating Margin
39.38%
+62.1pp
FY2021
Diluted EPS
-$1.94
+3%
FY2025
Operating Cash Flow
-$132.03M
+2.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $351.37M | $48.63M | — | — | |
| $159.57M | $148.02M | $144.1M | $114.24M | $81.94M | $167.21M | $38.02M | $10.17M | $6.68M | |
| $30.28M | $32.86M | $48.85M | $49.92M | $48.71M | $45.79M | $21.64M | $4.44M | $2.8M | |
| — | $416K | $416K | $416K | $260K | $29K | $19K | $17K | $17K | |
| $189.85M | $180.89M | $192.95M | $164.16M | $130.65M | $212.99M | $59.66M | $14.61M | $9.48M | |
| -$189.85M | -$180.89M | -$192.95M | -$164.16M | -$130.65M | $138.38M | -$11.03M | -$14.61M | -$9.48M | |
| — | — | — | — | — | 39.38% | -22.68% | — | — | |
| — | -$180.47M | -$192.53M | -$163.75M | -$130.39M | $138.41M | -$11.01M | -$14.59M | -$9.46M | |
| -$175.83M | -$164.51M | -$167.46M | -$134.94M | -$119.5M | $138.59M | -$10.95M | -$14.03M | — | |
| -$6.32M | -$6.16M | $925K | $1.02M | -$3.59M | $17.4M | — | — | — | |
| -$169.52M | -$158.35M | -$168.39M | -$135.96M | -$115.91M | $121.19M | -$10.95M | -$14.03M | -$9.06M | |
| — | — | — | — | — | 34.49% | -22.51% | — | — | |
| -$169.73M | -$158.41M | -$168.36M | -$135.07M | -$116.59M | $121.19M | -$10.95M | $0 | $0 | |
| USD/shares | — | -$1.94 | -$2.00 | -$1.63 | -$1.39 | $1.46 | -$0.51 | -$1.39 | — |
| USD/shares | — | -$1.94 | -$2.00 | -$1.63 | -$1.39 | $1.37 | -$0.51 | -$1.39 | — |
| shares | — | 81.5M | 84.26M | 83.39M | 83.25M | 82.82M | 21.59M | 10.09M | 10.04M |
| shares | — | 81.5M | 84.26M | 83.39M | 83.25M | 88.25M | 21.59M | 10.09M | 10.04M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $25.52M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.58×
EV/EBIT
—
Biotechnology median 26.69×
P/E (TTM)
—
Biotechnology median 7.06×
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1593899
CUSIP
04683R106
13F (30d)
13 filings
13 filers
Visit website
Investor relations